India Biotech starts phase three clinical trials of Covaxin
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Thursday
February 02, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
THURSDAY, FEBRUARY 02, 2023
India Biotech starts phase three clinical trials of Covaxin

Coronavirus chronicle

TBS Report
17 November, 2020, 07:45 pm
Last modified: 17 November, 2020, 07:54 pm

Related News

  • Covid remains a public health emergency, says WHO
  • Potential China wave is 'wild card' for ending Covid emergency: WHO advisors
  • WHO chief hopes Covid will no longer be emergency next year
  • The Prof Writes: Covid-19 - The one that got away from us
  • Long Covid remains a mystery, though theories are emerging

India Biotech starts phase three clinical trials of Covaxin

The company plans to enroll 26,000 participants in the largest efficacy test conducted in India

TBS Report
17 November, 2020, 07:45 pm
Last modified: 17 November, 2020, 07:54 pm
India Biotech starts phase three clinical trials of Covaxin
Bharat Biotech International Limited – a multidimensional biotechnology company specialising in product-oriented research and development – has started phase three clinical trials of its Covid-19 vaccine, Covaxin, on a large scale.
 
The company plans to enroll a total of 26,000 participants in the largest efficacy test conducted in India and the first phase three clinical trials of the Covid-19 vaccine.
 
As part of the trials, the participants will sign up at 25 trial sites across India in the next few months.
 
The volunteers will then take two doses of the vaccine at intervals of about 28 days.
 
Volunteers wishing to take part in this test must be over 18 years of age. Participants will be randomly divided to receive two six-micrograms (MCG) injections of Covaxin or two placebo shots.
 
A statement from the agency said the trial will be kept confidential, as investigators, volunteers and the company will not know who was placed in which groups.
 
So far, Covaxin has been tested on 1,000 participants in the first and second stage clinical trials and the agency says the vaccine has shown promising protection and immunity.
 
According to the government's clinical trial registry, eight of the 25 sites have received approval from their respective ethics committees for clinical trials.
 
According to the clinical trial criteria, each trial site has its own ethics committee that monitors whether the conducted trial is complying with ethics and research protocols.
 
Aligarh Muslim University (AMU) Vice-chancellor Tariq Mansoor said on Wednesday that he has registered as the first volunteer for the trial at the university.
 
According to the trial protocol, the final stage test to determine the effectiveness of a vaccine will first look at whether two-dose shots can prevent a patient from developing symptoms of Covid-19.
 
Secondly, the effectiveness of the vaccine at preventing severe Covid-19 symptoms and death in a patient will be measured.
Sai Prasad, executive director of Bharat Biotech, said last month that the company plans to launch its Covid-19 vaccine by June next year, unless the government decides to allow the vaccine to be used urgently on the basis of previous clinical trials.
 
If the data on effectiveness is positive, it could be launched in early February.
 
Then it will be the second vaccine to be introduced in India after Covishield of the Serum Institute.
 
Prasad said the company is spending around Rs150 crore on the third phase of testing and another Rs120-150 crore on setting up a new plant which will be commissioned by December.
 
Bharat Biotech has started production of some doses on its own responsibility at its Hyderabad plant, with a current annual production capacity of about 150 million doses.
 
In addition to setting up new plants, the company is trying to use a third installation to produce Covaxin.
 
"We are trying to build another large-scale plant like ours in Hyderabad in another city through which [old and new plants] we will increase Covaxin production from 500 million to 1 billion a year," Prasad said.

Top News

COVAXIN / Coronavirus

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • File photo
    Another shock for consumers as LPG price hiked to Tk1,498 per 12 kg cylinder
  •  Defying economic shocks, export earnings register 5.89% growth in January
    Defying economic shocks, export earnings register 5.89% growth in January
  • Photo: TBS
    Anti-govt movement can do nothing as people are with AL: Sheikh Hasina

MOST VIEWED

  • Tourists ride a tour bus in Hong Kong, China October 25, 2019. REUTERS/Ammar Awad
    Hong Kong says 'hello' to woo back visitors after Covid
  • People wearing face masks following the coronavirus disease (Covid-19) outbreak are seen at Beijing Daxing International Airport in Beijing, China July 23, 2020. Photo:Reuters
    Pandemic to paradise: Chinese tourists return to Bali after three years
  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs

Related News

  • Covid remains a public health emergency, says WHO
  • Potential China wave is 'wild card' for ending Covid emergency: WHO advisors
  • WHO chief hopes Covid will no longer be emergency next year
  • The Prof Writes: Covid-19 - The one that got away from us
  • Long Covid remains a mystery, though theories are emerging

Features

Six Jeep Wranglers and a special XJ Jeep Cherokee set out into the depths of Lalakhal, Sylhet for an experience of a lifetime. Photo: Ahbaar Mohammad

Jeep Life Bangladesh: A club for Jeep owners to harness the power of their vehicles

5h | Wheels
While the Padma bridge in operation is changing the lives of millions in the south for the better, passenger rush to Shimulia ghat died down. Photo: Masum Billah

How are the Shimulia ghat businesses faring after Padma bridge?

7h | Panorama
After so many investments going embarrassingly wrong, as was the case with Sam Bankman-Fried, perhaps tech investors’ preference for less experience will wane. Photo: Bloomberg

Are you the next Steve Jobs? Good luck raising money in 2023

7h | Panorama
An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

1d | Panorama

More Videos from TBS

Is Hathurusingha the most successful coach of Bangladesh?

Is Hathurusingha the most successful coach of Bangladesh?

20h | TBS SPORTS
Semiconductor, pharma should get more attention

Semiconductor, pharma should get more attention

22h | TBS Round Table
Dhali Al Mamun’s art depicts colonial impact

Dhali Al Mamun’s art depicts colonial impact

21h | TBS Stories
Jewel's humanitarian store

Jewel's humanitarian store

19h | TBS Stories

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Leepu realised his love for cars from a young age and for the last 40 years, he has transformed, designed and customised hundreds of cars. Photo: Collected
Panorama

'I am not crazy about cars anymore': Nizamuddin Awlia Leepu

3
Photo: Collected
Energy

8 Ctg power plants out of production

4
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

5
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

6
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]